Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,690 across all filing types
Latest filing 2016-10-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
2016年第三季度报告全文
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2016 Third Quarter Report" of Changchun Dirui Medical Technology Co., Ltd. It contains detailed financial data, including balance sheets, profit and loss statements, cash flow analysis, shareholder information, risk factors, management discussion and analysis, and other comprehensive financial and operational details for the third quarter of 2016. The length is substantial (15,000 characters), and it includes actual financial statements and substantive analysis rather than just an announcement or summary. The content matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial data and analysis. Therefore, the correct classification is IR with high confidence. 9M 2016
2016-10-24 Chinese
关于化学发光试剂产品获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates for a series of chemical luminescence reagent products. It includes product names, registration certificate numbers, and validity periods. There is no financial data, no mention of financial results, no discussion of management changes, no voting results, no legal proceedings, and no mention of any report publication. The document is a regulatory announcement about product certification, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory announcement about product registration, so it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2016-10-21 Chinese
2016年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2016, providing estimated net profit figures and explanations for changes in performance. It explicitly states that the forecast has not been audited and that detailed financial data will be disclosed in the company's third quarter report. The document is short (1103 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2016
2016-10-14 Chinese
关于限售股份解禁上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Changchun Dirui Medical Technology Co., Ltd. regarding the lifting of restrictions on certain shares (limited shares) and their subsequent listing for trading. It details the number of shares becoming tradable, the shareholders involved, compliance with prior commitments, and regulatory approvals. The document does not contain financial statements or detailed financial analysis but is a regulatory disclosure about share circulation changes. It is not an annual report, earnings release, or management report. The document fits the category of Share Issue/Capital Change announcements, specifically about restricted shares becoming freely tradable, which is a capital structure change. The document length is 2578 characters, relatively short, and it is a direct announcement, not a report publication notice or certification. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2016-09-27 Chinese
国信证券股份有限公司关于公司限售股份上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal verification opinion from Guosen Securities regarding the listing and circulation of restricted shares of Changchun Dirui Medical Technology Co., Ltd. It references regulatory rules and confirms compliance with share lock-up commitments and legal requirements. The document is a verification or audit opinion related to share circulation, not a full annual or quarterly report, nor an announcement of voting results or capital changes. It is a standalone audit-type report focusing on compliance and verification of share circulation conditions. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 2552 characters, which is consistent with a detailed audit opinion rather than a brief announcement or a full financial report. FY 2016
2016-09-27 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Changchun Dirui Medical Technology Co., Ltd. regarding the progress of using idle self-owned funds to purchase financial products. It details the amounts, types, and expected returns of these financial products, along with risk disclosures and risk control measures. The document is relatively short (2549 characters) and focuses on a specific financing activity related to the company's use of funds for investment in financial products. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it provides an update on the company's financing activities involving the use of idle funds for investment purposes.
2016-09-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.